Meeting
2022 ASCO Annual Meeting
Real-world treatment patterns and clinical outcomes with first-line therapy in cisplatin-eligible and ineligible patients with advanced urothelial carcinoma.
Authors
Guru P. Sonpavde
Dana Farber Cancer Institute, Boston, MA
Guru P. Sonpavde , Matt D. Galsky , Phoebe Wright , Zsolt Hepp , Nancy N. Chang , Candice Willmon , Steven Sesterhenn , Yutong Liu , Alicia K. Morgans
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4565)
DOI
10.1200/JCO.2022.40.16_suppl.4565
Abstract #
4565
Poster Bd #
56
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Real-world treatment patterns and clinical outcomes among patients with metastatic urothelial carcinoma.
First Author: Daniel M. Geynisman
Poster
2024 ASCO Genitourinary Cancers Symposium
Pemetrexed (PEM) maintenance versus observation (OBS) in patients (pts) with advanced urothelial carcinoma (aUC) who completed first-line (1L) platinum-based chemotherapy (CTx) without disease progression (PREMIER, KCSG GU16-05).
First Author: Inkeun Park
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world (rw) treatment patterns, sequencing, and outcomes in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) receiving avelumab first-line maintenance (1LM) in the US.
First Author: Helen H. Moon
Poster
2023 ASCO Annual Meeting
Outcomes by complete response to first-line pembrolizumab or platinum-based chemotherapy in advanced urothelial carcinoma (UC) in KEYNOTE-361.
First Author: Ozgur Ozyilkan